Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 27.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Ap |
| 03.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | amount, or range of amounts, of these charges. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 26.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 27.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 28.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Unternehmen & Branche
| Name | Kezar Life Sciences, Inc. |
|---|---|
| Ticker | KZR |
| CIK | 0001645666 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 53,8 Mio. USD |
| Beta | 0,43 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -56,033,000 | -7.66 | 76,647,000 | 70,073,000 |
| 2025-09-30 | 10-Q | -11,227,000 | -1.53 | 97,726,000 | 82,976,000 | |
| 2025-06-30 | 10-Q | -13,704,000 | -1.87 | 109,123,000 | 91,786,000 | |
| 2025-03-31 | 10-Q | -16,556,000 | -2.27 | 125,260,000 | 103,069,000 | |
| 2024-12-31 | 10-K | 0 | -83,736,000 | -11.49 | 144,682,000 | 116,916,000 |
| 2024-09-30 | 10-Q | 0 | -20,313,000 | -2.78 | 164,086,000 | 134,049,000 |
| 2024-06-30 | 10-Q | -21,547,000 | -2.96 | 179,921,000 | 150,685,000 | |
| 2024-03-31 | 10-Q | -21,658,000 | -2.98 | 199,130,000 | 169,121,000 | |
| 2023-12-31 | 10-K | 7,000,000 | -101,870,000 | -14.04 | 221,235,000 | 187,570,000 |
| 2023-09-30 | 10-Q | 7,000,000 | -23,103,000 | -3.18 | 249,326,000 | 215,994,000 |
| 2023-06-30 | 10-Q | -24,308,000 | -0.34 | 263,379,000 | 232,277,000 | |
| 2023-03-31 | 10-Q | -22,199,000 | -0.31 | 284,180,000 | 252,490,000 | |
| 2022-12-31 | 10-K | 0 | -68,239,000 | -10.13 | 299,568,000 | 269,872,000 |
| 2022-09-30 | 10-Q | 0 | -17,847,000 | -0.25 | 304,770,000 | 283,188,000 |
| 2022-06-30 | 10-Q | -16,187,000 | -0.25 | 317,502,000 | 297,364,000 | |
| 2022-03-31 | 10-Q | -16,024,000 | -0.26 | 251,866,000 | 232,315,000 | |
| 2021-12-31 | 10-K | 0 | -54,630,000 | -1.04 | 217,933,000 | 196,876,000 |
| 2021-09-30 | 10-Q | -14,462,000 | -0.28 | 130,889,000 | 119,481,000 | |
| 2021-06-30 | 10-Q | -12,962,000 | -0.25 | 139,672,000 | 129,886,000 | |
| 2021-03-31 | 10-Q | -12,994,000 | 152,337,000 | 140,637,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-07-02 | Schiller Mark C. | Officer, Chief Operating Officer | Open Market Sale | -561 | 4.28 | -2,401.08 | -136,0% | |
| 2025-07-02 | Chiang Pichi Luo | Officer, SVP, Corporate Controller | Open Market Sale | -264 | 4.28 | -1,129.92 | -64,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.